Tycho Peterson
Stock Analyst at JP Morgan
(5.00)
# 1
Out of 4,906 analysts
130
Total ratings
64.84%
Success rate
269.21%
Average return
Main Sectors:
Stocks Rated by Tycho Peterson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Overweight | $160 → $155 | $112.04 | +38.34% | 8 | May 29, 2025 | |
| WGS GeneDx Holdings | Upgrades: Buy | $80 | $78.35 | +2.11% | 1 | May 9, 2025 | |
| QDEL QuidelOrtho | Upgrades: Buy | $44 | $25.30 | +73.91% | 6 | May 8, 2025 | |
| MTD Mettler-Toledo International | Upgrades: Hold | $1,200 → $1,100 | $1,166.48 | -5.70% | 8 | May 5, 2025 | |
| DHR Danaher | Maintains: Overweight | $280 → $260 | $188.07 | +38.25% | 3 | Apr 22, 2025 | |
| LH Labcorp Holdings | Maintains: Buy | $275 → $290 | $243.04 | +19.32% | 2 | Feb 6, 2025 | |
| NEO NeoGenomics | Initiates: Buy | $22 | $6.21 | +254.27% | 1 | Dec 10, 2024 | |
| DGX Quest Diagnostics | Assumes: Buy | $185 | $166.45 | +11.14% | 1 | Dec 10, 2024 | |
| HOLX Hologic | Initiates: Hold | $85 | $63.68 | +33.48% | 7 | Dec 10, 2024 | |
| QGEN Qiagen | Assumes: Buy | $43 → $56 | $48.07 | +15.71% | 5 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $415 | $281.66 | +47.34% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $35 | $34.79 | +0.60% | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $115 → $125 | $90.72 | +37.79% | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $11.54 | +107.97% | 7 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $1.45 | +175.86% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $5 → $3 | $0.73 | +312.65% | 1 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $142 | $140.63 | +0.97% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $45.64 | -29.89% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $115 | $94.80 | +21.31% | 1 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underperform | $25 → $20 | $4.45 | +349.44% | 1 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $600 → $650 | $404.94 | +60.52% | 12 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $26 → $9 | $11.01 | -18.26% | 1 | Sep 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.45 | - | 2 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $12 | $2.14 | +462.06% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $60 | $5.18 | +1,058.30% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.44 | +568.60% | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $375 → $390 | $149.79 | +160.36% | 5 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $3.25 | +453.85% | 1 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $188 → $200 | $516.12 | -61.25% | 9 | Jun 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $19.47 | +23.27% | 3 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $45 | $15.64 | +187.82% | 5 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $114.80 | -39.02% | 2 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $120 | $158.96 | -24.51% | 1 | Feb 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.34 | - | 7 | Dec 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.64 | - | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $55 | $16.04 | +242.89% | 1 | Jul 19, 2016 |
Agilent Technologies
May 29, 2025
Maintains: Overweight
Price Target: $160 → $155
Current: $112.04
Upside: +38.34%
GeneDx Holdings
May 9, 2025
Upgrades: Buy
Price Target: $80
Current: $78.35
Upside: +2.11%
QuidelOrtho
May 8, 2025
Upgrades: Buy
Price Target: $44
Current: $25.30
Upside: +73.91%
Mettler-Toledo International
May 5, 2025
Upgrades: Hold
Price Target: $1,200 → $1,100
Current: $1,166.48
Upside: -5.70%
Danaher
Apr 22, 2025
Maintains: Overweight
Price Target: $280 → $260
Current: $188.07
Upside: +38.25%
Labcorp Holdings
Feb 6, 2025
Maintains: Buy
Price Target: $275 → $290
Current: $243.04
Upside: +19.32%
NeoGenomics
Dec 10, 2024
Initiates: Buy
Price Target: $22
Current: $6.21
Upside: +254.27%
Quest Diagnostics
Dec 10, 2024
Assumes: Buy
Price Target: $185
Current: $166.45
Upside: +11.14%
Hologic
Dec 10, 2024
Initiates: Hold
Price Target: $85
Current: $63.68
Upside: +33.48%
Qiagen
Dec 10, 2024
Assumes: Buy
Price Target: $43 → $56
Current: $48.07
Upside: +15.71%
Oct 8, 2024
Upgrades: Buy
Price Target: $355 → $415
Current: $281.66
Upside: +47.34%
Aug 5, 2024
Maintains: Underweight
Price Target: $28 → $35
Current: $34.79
Upside: +0.60%
Jul 29, 2024
Maintains: Hold
Price Target: $115 → $125
Current: $90.72
Upside: +37.79%
Jul 22, 2024
Upgrades: Buy
Price Target: $24
Current: $11.54
Upside: +107.97%
Jun 3, 2024
Initiates: Buy
Price Target: $4
Current: $1.45
Upside: +175.86%
Jun 3, 2024
Assumes: Hold
Price Target: $5 → $3
Current: $0.73
Upside: +312.65%
Jun 3, 2024
Initiates: Buy
Price Target: $142
Current: $140.63
Upside: +0.97%
Jun 3, 2024
Initiates: Buy
Price Target: $32
Current: $45.64
Upside: -29.89%
Jun 3, 2024
Assumes: Hold
Price Target: $115
Current: $94.80
Upside: +21.31%
Jun 3, 2024
Assumes: Underperform
Price Target: $25 → $20
Current: $4.45
Upside: +349.44%
Jun 3, 2024
Assumes: Buy
Price Target: $600 → $650
Current: $404.94
Upside: +60.52%
Sep 21, 2022
Downgrades: Underweight
Price Target: $26 → $9
Current: $11.01
Upside: -18.26%
Aug 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.45
Upside: -
Aug 11, 2022
Downgrades: Neutral
Price Target: $20 → $12
Current: $2.14
Upside: +462.06%
Mar 2, 2022
Maintains: Overweight
Price Target: $85 → $60
Current: $5.18
Upside: +1,058.30%
Aug 17, 2021
Initiates: Overweight
Price Target: $23
Current: $3.44
Upside: +568.60%
May 28, 2021
Maintains: Overweight
Price Target: $375 → $390
Current: $149.79
Upside: +160.36%
Aug 10, 2020
Initiates: Neutral
Price Target: $18
Current: $3.25
Upside: +453.85%
Jun 18, 2020
Maintains: Overweight
Price Target: $188 → $200
Current: $516.12
Upside: -61.25%
Jun 1, 2020
Maintains: Overweight
Price Target: $22 → $24
Current: $19.47
Upside: +23.27%
Mar 17, 2020
Maintains: Neutral
Price Target: $65 → $45
Current: $15.64
Upside: +187.82%
Nov 2, 2018
Maintains: Overweight
Price Target: $60 → $70
Current: $114.80
Upside: -39.02%
Feb 15, 2018
Maintains: Overweight
Price Target: $115 → $120
Current: $158.96
Upside: -24.51%
Dec 13, 2017
Downgrades: Underweight
Price Target: n/a
Current: $1.34
Upside: -
Nov 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $35.64
Upside: -
Jul 19, 2016
Initiates: Neutral
Price Target: $55
Current: $16.04
Upside: +242.89%